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A report on the Contemporary Concepts in Toxicology
workshop ‘Use of Genomic Data in Risk Assessment: State
of the Art 2001’ held by the Society of Toxicology,
Washington DC, USA, 7-8 November 2001.
“In  the  21st  century,  the  new  genomic  technologies  will
greatly  improve  the  accuracy  of  risk  assessment,  allowing
identification  of  sensitive  subpopulations  and,  ultimately,
allow personalized risk profiling for each individual based on
their genetic composition”. So declared the announcement
for  the  Contemporary  Concepts  in  Toxicology  meeting,  a
workshop  designed  to  examine  the  genomic  technologies
that  might  be  applied  to  such  risk  assessment  and  their
implications for risk characterization and understanding of
gene interactions. Three significant areas of risk assessment
were considered: the risk from inadvertent exposure to envi-
ronmental  toxicants;  the  risk  of  adverse  response  to  pre-
scribed pharmaceuticals; and the risk of developing disease
because of genetic predisposition.
John Weinstein (National Cancer Institute, Bethesda, USA)
emphasized in the plenary talk that there has to be a synergy
between the new ‘-omic’ research and traditional hypothesis-
driven science, and that there are now a number of useful
genomic  technologies,  including  comparative  genomic
hybridization, single-nucleotide polymorphism (SNP) analy-
sis,  restriction  landmark  genome  scanning,  and  spectral
karyotyping. ‘Transcriptomics’ is the current dominant force
in genomics, however, and Edwin Clark (Millennium Phar-
maceuticals, Cambridge, USA) reported the use of differen-
tial  expression  analysis  to  elucidate  markers  that  indicate
whether  a  patient  has  an  increased  risk  of  developing
ovarian cancer. Transcript profiling was used in drug-dis-
covery studies to identify possible drug targets, and in effi-
cacy studies to identify biomarkers that allow prediction of a
patient’s response to chemotherapy. No further details about
the  markers  or  the  drug  targets  analyzed  were  presented.
Clark  also  described  how  pharmacogenomics  tests  carried
out ex vivo on cancer biopsies could help to identify respon-
ders and non-responders to drug treatment, as defined by
the expression of selected genetic biomarkers, allowing the
use of alternative therapies if a patient is found to be a prob-
able non- or adverse responder to the standard drug. 
SNP analysis is an important component of the arsenal of
genomic techniques, and Arthur Holden (First Genetic Trust
Inc., North Deerfield, USA) described how The SNP Consor-
tium  (TSC)  [http://snp.cshl.org]  was  established  through
the collaboration of multiple organizations to advance the
field of medicine and aid the development of genetics-based
diagnostics and therapeutics. SNPs are the most widespread
and stable form of genetic variation, are easy to detect and
can be stored as digital code. TSC has so far identified 1.7
million SNPs, 1.4 million of which are described as ‘unen-
cumbered’ - that is, they have no intellectual property rights
attached.  Doug  Bell  (National  Institute  of  Environmental
Health  Sciences  (NIEHS),  Research  Triangle  Park,  USA)
presented some well-characterized examples of genetic poly-
morphisms  modifying  exposure-related  responses;  for
example, heterozygote carriers of the mutation that causes
sickle cell anemia show reduced susceptibility to malaria, a
polymorphism in the cytochrome 450 form CYP2D6 affects
adverse  drug  responses,  and  alcohol  intolerance  is  influ-
enced  by  polymorphisms  in  aldehyde  dehydrogenase.  Bell
warned, however, that determining a quantitative measure
of exposure is difficult in humans, so combining this with
genetic information to assess risk is quite problematic. There
is thus a need to determine functional relationships between
genotype  and  phenotype,  remembering  that  simple  poly-
morphisms  may  have  different  effects  depending  on  the
chemical and the target organs that are considered.
It appears likely that genomic data will find, and possibly
even require, some support from proteomic studies. Whenexamining the correlation coefficients for mRNA and protein
expression in human gliomas and lung cancer, Sam Hanash
(University of Michigan, Ann Arbor, USA) found that mRNA
and protein expression levels showed good correlation for
some genes, while they did not for others, and in some cases
they were even negatively correlated (perhaps as a result of
negative  feedback).  Hanash  thus  proposed  that  evaluating
the cellular response to a toxic challenge should not neces-
sarily be based on changes in gene expression per se, but on
how the expression relationship changes between a specific
mRNA and the corresponding protein.
Harvey Mohrenweiser (Lawrence Livermore National Labo-
ratory,  Livermore,  USA)  has  been  considering  the  genetic
mechanisms underlying cancer susceptibility, in particular
the roles of DNA-repair genes. He reasoned that it is not the
amount of DNA damage a cell sustains per se that produces
a cancerous phenotype, but the amount of damage present at
the time of cell division. He referred to a published study
(Wu et al., Cancer 1998, 83:1118-1127), which reported that
sensitivity of cells to benzo[a]pyrene diol epoxide (BPDE, a
metabolic  product  of  benzo[a]pyrene,  a  constituent  of
tobacco smoke) was significantly associated with lung carci-
noma,  and  suggested  that  variation  in  BPDE  sensitivity
might  be  due  to  different  repair  or  sensitivity  pathways.
Mohrenweiser is thus currently assessing whether genotypes
associated with reduced repair capacity can be used as bio-
markers of increased cancer risk. A similar view was con-
veyed  by  Jim  MacGregor  (Food  and  Drug  Administration
(FDA), Rockville, USA) when he suggested that elucidation
of the molecular systems that protect and repair cell function
will provide a new generation of surrogate biomarkers for
monitoring cell damage. MacGregor was, however, reluctant
to predict when the FDA would be in a position to accept
data from new genomic methods as support for applications
for FDA approval. He said this would occur “when it’s appro-
priate”, namely, when there is consensus within the scien-
tific community and the responsible FDA center about the
suitability  of  any  given  approach.  MacGregor  anticipated
that no single genomic technology will meet all assessment
needs,  but  that  different  methods  will  predominate  under
different circumstances. He also predicted that risk assess-
ment  will  embrace  an  increasingly  multidisciplinary
approach requiring the integration of pharmacology, toxicol-
ogy, pharmacokinetics and other disciplines. 
While many of the speakers discussed the application of
genomics to the clinic, for example, by identifying the pos-
sibility of adverse drug reactions and determining genetic
predisposition  to  disease  development, Bill  Farland  (US
Environmental Protection Agency (EPA), Washington DC,
USA) provided an overview of how genomics might aid the
risk assessment process for environmental exposure. Such
exposures occur through air, water and food, and are often
inadvertant, unknown or inescapable. Genomics, he pre-
dicted,  will  be  particularly  useful  in  identifying  and
demonstrating  the  mode  of  action  of  any  toxic  effects
through highlighting the gene-expression networks and/or
pathways that are affected. Such information will also help
identify and measure key events (for example, changes fol-
lowing receptor-ligand interaction or changes in DNA and
chromosomes, such as DNA strand breaks or base modifica-
tions induced by environmental toxicants) that are useful in
risk assessment. Genomics will also help our understanding
of whether toxicology data generated from animal models
are relevant to human health. George Gray (Harvard Center
for  Risk  Analysis,  Boston,  USA)  added  that  although
genomic information has real potential to improve risk pre-
diction, changes in genotype or phenotype per se may not be
relevant to risk, and variability between individuals in expo-
sure and sensitivity must be incorporated into the risk analy-
sis  process.  For  example,  some  individuals  smoke  40
cigarettes a day all their life without developing lung cancer,
whereas others who smoke much less may develop cancer at
a  relatively  early  age.  Many  smokers  show  characteristic
genetic or phenotypic changes in their lung epithelia that are
generally  indicative  of  increased  risk  of  progressing  to  a
disease state. For some individuals, however, these changes
do  not  represent  a  significantly  increased  risk  as  certain
genetic makeups and/or life style and environmental factors
(notably diet) may strongly reduce the possibility of further
disease progression. He also made a plea for greater interac-
tion between toxicologists and regulators, as the latter often
rely on the former to identify specific risk indicators. 
Dale  Hattis  (Clark  University,  Worcester,  USA)  suggested
that genomic analysis may be less relevant for risk assess-
ment than measuring functional phenotypes such as enzyme
activitation  or  deactivation  and  DNA-repair  function.  Like
many other speakers, he expressed the view that gene-expres-
sion profiling holds promise, but a good deal of work is still
needed, and it may be as long as ten years before such data
can be usefully incorporated into risk assessment for environ-
mental exposures. Many participants at the meeting hoped
that this will turn out to be a conservative estimate, and Ray
Tennant  (NIEHS,  Research  Triangle  Park,  USA)  provided
some  hope  for  this  when  he  reported  how  researchers  at
NIEHS have already successfully classified mRNA expression
profiles in animals exposed to certain chemicals. 
The use of genomic data in risk assessment also faces obsta-
cles in the form of the complex social, moral and legal issues
relating to the protection of human subjects, the privacy of
genetic information and the possibility of discriminatory use
of such data. The ethical, legal and social implications (ELSI)
program, spawned from the human genome project (HGP),
demonstrates  the  seriousness  with  which  scientists  and
policy makers are treating public skepticism over the control
of  powerful  genomic  technologies.  As  Richard  Sharp
(NIEHS,  Research  Triangle  Park,  USA)  pointed  out,
however, ELSI is funded in large part by the HGP budget
and there has been justifiable concern that the bioethicists
2 Genome Biology Vol 3 No 4  Rockettmay not be as independent as they should be. The main cri-
tique is that they have failed to properly address controver-
sial  issues,  such  as  the  cloning  of  embryos, and  their
testimony may inhibit the pace of science. Sharp concluded
that  the  scientific  community  should  be  mindful  that
although the services of bioethicists may currently be viewed
as a commodity, their involvement in research is neverthe-
less likely to increase and should be viewed as a mutually
beneficial  arrangement  that  can  facilitate  identification  of
ethical issues that would otherwise go unnoticed. 
There was general consensus that genomic techniques must
be improved so they can return more sensitive, reproducible
and quantitative data before they can realistically be used in
the risk-assessment process. There is also a need to standard-
ize and validate the protocols that are developed, and main-
tain rigorous quality control. The good news is that we can
anticipate such technical issues to be overcome in relatively
short course. Of more concern is how to interpret the vast
quantities of complex genomic data. Without a clear under-
standing of, for example, gene-environment interactions, dif-
ferences between species and individual responses, and the
qualitative  and  quantitative  linkages  between  toxicity  and
disease, there is real potential for disagreement or misinter-
pretation of data where risk assessment is concerned. Never-
theless, the field of genomics (and proteomics) is developing
fast; there will be many opportunities for applying genomics
and proteomics to risk assessment and these need to be rec-
ognized and acted upon by regulatory agencies such as the
EPA and FDA. Developing genomic (and proteomic) applica-
tions  will  require  significant  investment  in  both  basic  and
applied research, and the impact on regulatory practices will
make an agreement on certain policies necessary.
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